PeppiLibrary

Growth Hormone

Tesamorelin peptide reference

FDA-approved GHRH analog. Specifically reduces visceral fat in HIV lipodystrophy.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Tesamorelin notes
Default dose label2 mg
Preferred routeSubQ
Frequency label1× daily
Storage window1 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved with Phase 3 trials

Prescription medication (Egrifta)

Route map

How records are usually labeled

1 SubQ

Rotate around the abdomen daily to minimise lipoatrophy.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; protect from light.
After mixUse immediately; per label, do not store reconstituted solution.
Use-by cue1 days after mixing
Mixed vial window1 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 2 mg vial
Dose 2 mg
Route SubQ
Review 1d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Tesamorelin. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Tesamorelin is a stabilised 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus that resists DPP-4 degradation. It was FDA-approved in 2010 (as Egrifta) for the reduction of excess visceral abdominal fat in HIV patients with lipodystrophy — currently the only GHRH analog with a current FDA approval for body composition.

Also known as: Egrifta, TH9507.

HIV-associated lipodystrophy (FDA indication)Visceral adipose tissue reduction researchOff-label body-composition support

Mechanism and timing snapshot

GHRH-receptor agonist with extended stability via N-terminal modification. Stimulates pulsatile endogenous GH release; reduces visceral adipose tissue specifically.

Onset label15 min
Catalog onset field, when available.
Half-life label24 min
Plasma half-life ~26 min
Duration label3 hr
Catalog duration field, when available.
subQ Moderate
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose2 mg
Catalog dose range1 mg - 2 mg
Default routeSubQ
Frequency label1× daily
Best time labelSame time each day; bedtime aligns with natural GH pulse.
Food noteNone for the labelled indication, though empty stomach optimises GH response.

Catalog protocol note

2 mg subQ once daily for 6 months minimum (label dose for HIV lipodystrophy).

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate around the abdomen daily to minimise lipoatrophy.

Chemistry

SequenceModified GHRH(1-44); trans-3-hexenoic acid at N-terminus
Amino acids44
Molecular formulaC223H348N72O69S
Molecular weight5135.86 Da

Vial, reconstitution, and storage

Supply formLyophilized powder (single-use vial)
Typical vial size2 mg
DiluentSterile water (per label)
Diluent volume2.1 mL
Concentration note2 mg vial reconstituted with 2.1 mL → entire vial = 2 mg dose. Single-use only per label.
Before reconstitutionRefrigerate 2–8 °C; protect from light.
After reconstitutionUse immediately; per label, do not store reconstituted solution.
Reconstituted shelf life1 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Injection-site reactions (~25%)
  • Joint pain
  • Limb swelling
  • Muscle pain
  • Glucose intolerance / new-onset T2D (~3%)
  • Carpal tunnel symptoms

Contraindications and warnings

  • Pregnancy
  • Active malignancy
  • Pituitary disorders
  • Severe respiratory failure
  • Not for general weight loss — labelled only for HIV lipodystrophy.

Other considerations

  • The only GHRH analog with current FDA approval for body composition.
  • Effect on visceral fat is meaningful (-15-20% over 6 months in trials).

Evidence and regulatory context

Evidence levelFDA-approved with Phase 3 trials
FDA approvedYes
Regulatory statusPrescription medication (Egrifta)
Prescription requiredYes
Approved countriesUS, Canada

Stacking and cycle notes

Stacks well withipamorelin
Avoid combining noteOther GHRH analogs simultaneously
Typical cycle label26+
Typical break labelPer clinician
Cycle guidanceLong continuous courses (6–12 months) per label; effects regress on discontinuation.

Tracking tips

  • Per the label, reconstituted solution is single-use — don't try to store leftovers.
  • Monitor fasting glucose during use; ~3% develop glucose intolerance.
  • Expect 3–6 months for visible visceral fat reduction.

References

Track it in Peppi

Keep Tesamorelin records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Tesamorelin?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Tesamorelin?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Tesamorelin records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026